7 not yet recruiting, 7 recruiting, 2 completed. 4 Not applicable, 4 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Not yet recruiting 2, Completed 1, Recruiting 1 |
| Phase 1 | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Myasthenia Gravis (MG): new trials by email Literature Review of Myasthenia Gravis (MG) trials Research Report on Myasthenia Gravis (MG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis Myasthenia Gravis (MG), Myasthenia Gravis Associated With Thymoma | Not yet recruiting | IRCCS San Raffaele | 40 | 2026-09-15 | 2026-05-06 | |
| Feasibility of Remote Monitoring of Patients With Myasthenia Gravis Myasthenia Gravis (MG) | Recruiting | George Washington University | 18 | 2026-08-19 | 2026-10-05 | |
| Sexual and Urinary Dysfunctions in Generalized Myasthenia No intervetion - Myasthenia Gravis (MG) | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 150 | 2026-07-30 | 2026-07-01 | |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS - AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG) | Phase 2 | Recruiting | argenx | 40 | 2026-07-10 | 2026-10-16 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases MTM-H-001 Injection - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not applicable | Not yet recruiting | Beijing GoBroad Hospital | 75 | 2026-06-01 | 2026-05-18 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| The Effectiveness of an ETP Programme in Myasthenia Gravis: a Proof-of-concept Study. CBSM - Myasthenia Gravis (MG) | Not yet recruiting | University Hospital, Grenoble | 62 | 2026-04-01 | 2026-04-06 | |
| Talquetamab in Patients With Refractory Generalized Myasthenia Gravis Talquetamab - Myasthenia Gravis (MG) | Not applicable | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | 2 | 2026-03-20 | 2026-04-08 |
| AXIS MG Patient Registry Myasthenia Gravis (MG), Myasthenia Gravis, Generalized | Recruiting | Autoimmune Neurology Alliance | 1000 | 2026-03-19 | 2026-08-17 | |
| Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases EVM18001 Injection - System Lupus Erythematosus(SLE), Scleroderma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-03-12 | 2026-03-13 |
| Ripertamab for the Treatment of Myasthenia Gravis ripertamab - Myasthenia Gravis (MG) | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 20 | 2026-02-01 | 2026-01-28 |
| CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning - Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Early Phase 1 | Recruiting | Tongji Hospital | 36 | 2025-12-12 | 2026-05-12 |
| Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases HBI0101 CART - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM) | Phase 1 | Recruiting | Polina Stepensky | 120 | 2024-09-01 | 2026-05-06 |
| Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis Myasthenia Gravis (MG) | Completed | Beijing University of Chinese Medicine | 231 | 2024-01-01 | 2026-03-16 | |
| Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria. IVIG (Intravenous Immunoglobulin), Plasma exchange (PE) - Myasthenic Crisis, Myasthenia Gravis (MG) | Not applicable | Completed | Damascus University | 50 | 2022-09-01 | 2026-04-16 |
Myasthenia Gravis (16) · Multiple Sclerosis (5) · Autoimmune Diseases of the Nervous System (3) · Lupus Erythematosus, Systemic (3) · Neuromyelitis Optica (3) · Arthritis, Rheumatoid (2) · Myositis (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Recurrence (2) · Scleroderma, Systemic (2) · Antiphospholipid Syndrome (1) · Autoimmune Diseases (1) · Disease Progression (1) · Immunoglobulin G4-Related Disease (1) · Lupus Nephritis (1)
Immune System Diseases (16) · Neoplasms (16) · Neoplasms by Site (16) · Nervous System Diseases (16) · Nervous System Neoplasms (16) · Neurodegenerative Diseases (16) · Neuromuscular Diseases (16) · Paraneoplastic Syndromes (16) · Paraneoplastic Syndromes, Nervous System (16) · Autoimmune Diseases (15) · Neuromuscular Junction Diseases (15) · Autoimmune Diseases of the Nervous System (13) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Disease Attributes (5)
Cyclophosphamide (1) · Immunoglobulins, Intravenous (1) · Plasma Exchange (1) · fludarabine (1) · talquetamab (1)
Tongji Hospital (2) · Autoimmune Neurology Alliance (1) · Beijing GoBroad Hospital (1) · Beijing University of Chinese Medicine (1) · Centre Hospitalier Universitaire de Nice (1) · Damascus University (1) · First Affiliated Hospital of Chongqing Medical University (1) · George Washington University (1) · IRCCS San Raffaele (1) · Polina Stepensky (1) · The Affiliated Hospital of Qingdao University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University Hospital, Grenoble (1) · Zhongming Qiu (1) · argenx (1)
China (6) · United States (3) · France (1) · Greece (1) · Israel (1) · Italy (1) · Spain (1) · Syria (1)
Chuan Qin (1) · Chuan Qin, Prof. (1) · Daishi Tian (1) · Daishi Tian, Prof. (1) · Gary R Cutter, PhD (1) · Jared R Adams, MD, PhD (1) · Jing Pan, Ph.D (1) · Mohammad Shehadeh Agha, MD, PhD (1) · Neelam Goyal, MD (1) · Qiubai Li, Professor (1) · Richard J Nowak, MD, MS (1) · Srikanth Muppidi, MD (1) · Stefano C Previtali (1)
PMID 21670440, PMID 23235588, PMID 23956564, PMID 27358333, PMID 28916122, PMID 39376877
2025 (1)